Micoxolamina

Ciclopirox olamine, the active ingredient in Micoxolamina, is an antifungal presented as a topical formulation for skin application. It is used to treat superficial fungal infections of the skin and nails, providing a broad‑spectrum option for patients with dermatophyte, yeast, or mold infections and are commonly prescribed by dermatologists.

GNH USA supplies Micoxolamina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Micoxolamina is a topical antifungal that targets superficial fungal infections of the skin and nails. - Athlete’s foot (tinea pedis): reduces fungal growth and alleviates itching and scaling. - Ringworm (tinea corporis): clears lesions and prevents spread. - Nail fungus (onychomycosis): improves nail appearance and reduces fungal load.

Micoxolamina may cause local skin reactions when applied.

Common Side Effects: - Irritation: mild burning or stinging at the application site. - Redness: localized erythema around the treated area. - Dryness: skin may become dry or flaky. - Itching: occasional pruritus during treatment. - Scaling: superficial skin flaking.

Serious or Rare Side Effects: - Allergic contact dermatitis: severe rash with swelling. - Bullous dermatitis: blister formation on the skin. - Photosensitivity: increased sensitivity to sunlight. - Systemic absorption reactions: rare hepatic or renal effects. - Severe skin necrosis: extensive tissue damage (very rare).

When using Micoxolamina, consider the following safety measures. - Avoid use on damaged skin: do not apply to open wounds or severe eczema. - Limit exposure to eyes: keep product away from the ocular area. - Do not use on mucous membranes: avoid oral, genital, or anal mucosa. - Discontinue if severe irritation occurs: seek medical advice promptly. - Store at room temperature: keep in the original container, protect from moisture and light.

Micoxolamina has a low potential for systemic drug interactions, but topical co‑applications may affect tolerability.

Major Interactions (Avoid): - Concurrent use with other topical irritants: may increase skin irritation. - Use with systemic antifungals that share hepatic metabolism: monitor liver function.

Moderate Interactions (Monitor Closely): - Co‑application with corticosteroid creams: may reduce antifungal efficacy. - Use with phototoxic agents: increase risk of photosensitivity. - Combination with other topical medications: assess for additive irritation.